|
|
|
|
|
|
By Ed Silverman
Adobe
The upcoming trial will be the first to test arguments made by numerous cities, counties, and others that drug makers and distributors fomented the crisis.
Read More
|
|
By Adam Feuerstein
Ruby Wallau for STAT
Some thoughts, analysis, and lingering questions for investors trying to figure out what the FDA's decision on the company's Duchenne drug is all about.
Read More
|
|
By Matthew Herper
Dom Smith/STAT
The scientist, Brian Kaspar, said through a lawyer that he was “prepared to assert his rights and defend his conduct accordingly."
Read More
|
|
Sponsor content by STAT Events
The 2019 STAT Summit: The Next Breakthroughs
This November, we’re bringing STAT’s award-winning coverage to life and assembling top biotech, pharma, and life sciences executives, researchers, health care policymakers, and patient advocates for our inaugural STAT Summit. The goal: to convene the top minds in health care and to set the agenda for the future of medicine. Learn more.
|
|
By Shraddha Chakradhar
Courtesy Ciji Green
Their success reflects not only the effectiveness of public pressure campaigns but also the stakes for families whose children have the rare disease.
Read More
|
|
By Ed Silverman
Adobe
American Regent revamped the only essential mineral used by hospitals for feeding patients intravenously recently and raised the price by a whopping 1,300%.
Read More
|
|
By Elizabeth Baker
Sherman/Getty Images
Tools for testing drug safety that use approaches based on human biology should be qualified under the FDA's drug development tools program.
Read More
|
|
By Ed Silverman
Alex Hogan/STAT
Twice in 2017, the company gave Wall Street sell-side analysts material, non-public information about an estrogen therapy for postmenopausal women.
Read More
|
|
